Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin C Creelan

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Update on immune checkpoint inhibitors in lung cancerBenjamin C Creelan
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Current clinical application of genomic and proteomic profiling in non-small-cell lung cancerTawee Tanvetyanon, Benjamin C Creelan, Alberto A Chiappori
Expert Review of Anticancer Therapy|August 5, 2016
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancerTawee Tanvetyanon, Benjamin C Creelan, Scott J Antonia
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2024
Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New ChallengesGiannis Mountzios, Jarushka Naidoo, Chao Wang, et al.
JTO Clinical and Research Reports|December 4, 2023
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299Arkadiusz Z Dudek, Min X Xi, Katherine A Scilla, et al.
Oncology (Williston Park, N.Y.)|December 19, 2015
Propelling Immunotherapy Combinations Into the ClinicNishan Tchekmedyian, Jhanelle E Gray, Benjamin C Creelan, et al.
Clinical Lung Cancer|May 8, 2024
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy AloneMatthew N Mills, Akihiro Uno, Pinxue Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase InhibitorsMatthew A Smith, Thomas Licata, Aliya Lakhani, et al.
Cancer|October 30, 2022
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumorsAung Naing, Alain P Algazi, Gerald S Falchook, et al.
British Journal of Cancer|October 5, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancerBenjamin C Creelan, Tammie C Yeh, Sang-We Kim, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Update on immune checkpoint inhibitors in lung cancerBenjamin C Creelan
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Current clinical application of genomic and proteomic profiling in non-small-cell lung cancerTawee Tanvetyanon, Benjamin C Creelan, Alberto A Chiappori
Expert Review of Anticancer Therapy|August 5, 2016
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancerTawee Tanvetyanon, Benjamin C Creelan, Scott J Antonia
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 23, 2024
Beyond Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer: New Frontiers, New ChallengesGiannis Mountzios, Jarushka Naidoo, Chao Wang, et al.
JTO Clinical and Research Reports|December 4, 2023
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299Arkadiusz Z Dudek, Min X Xi, Katherine A Scilla, et al.
Oncology (Williston Park, N.Y.)|December 19, 2015
Propelling Immunotherapy Combinations Into the ClinicNishan Tchekmedyian, Jhanelle E Gray, Benjamin C Creelan, et al.
Clinical Lung Cancer|May 8, 2024
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy AloneMatthew N Mills, Akihiro Uno, Pinxue Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2017
MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase InhibitorsMatthew A Smith, Thomas Licata, Aliya Lakhani, et al.
Cancer|October 30, 2022
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumorsAung Naing, Alain P Algazi, Gerald S Falchook, et al.
British Journal of Cancer|October 5, 2020
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancerBenjamin C Creelan, Tammie C Yeh, Sang-We Kim, et al.
Pageof 2